Mumbai: Turtlemint Fintech Solutions is set to launch its initial public offering (IPO) on June 19, offering investors an opportunity to participate in one of India’s leading insurtech platforms. The Rs 883 crore public issue comprises a combination of a fresh issue of shares and an offer-for-sale (OFS) by existing shareholders. Market participants will closely track the IPO as they evaluate the company’s growth potential, valuation and financial performance.
The IPO comes amid continued investor interest in technology-driven financial services companies and the rapidly evolving insurance distribution sector. Turtlemint has established itself as a major player in India’s insurtech space through its extensive network of insurance advisors and digital platform.
IPO details and price band
Turtlemint has fixed the price band for the issue at Rs 144 to Rs 152 per equity share. At the upper end of the price band, the company is valued at more than Rs 4,500 crore.
The public issue will open for subscription on June 19 and is expected to remain available for bidding as per the schedule announced in the prospectus. Shares are proposed to be listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
According to the tentative schedule, the basis of allotment is expected to be finalised on June 24, while the company’s shares are likely to debut on the stock exchanges on June 29.
The IPO consists of a fresh issue of equity shares worth up to Rs 660.72 crore. In addition, existing shareholders will offload approximately 1.46 crore equity shares through the OFS component, aggregating to around Rs 221.95 crore.
Grey market premium remains subdued
The grey market premium (GMP) for the Turtlemint Fintech IPO has softened in recent days, indicating cautious sentiment among market participants.
As of 1:02 pm on June 18, 2026, the IPO was commanding a GMP of Rs 2.5 per share. Based on the upper price band of Rs 152, the estimated listing price stands at around Rs 154.5 per share.
This translates into an expected listing gain of approximately 1.64 per cent. While GMP is not an official indicator and can fluctuate significantly before listing, it is often used by investors to gauge market sentiment towards an IPO.
The relatively modest premium suggests that investors are adopting a wait-and-watch approach despite the company’s strong growth trajectory in recent years.
Shareholder participation and allocation structure
Several existing investors and promoters are participating in the OFS component of the issue.
Promoters Anand Rohidas Prabhudesai and Dhirendra Nalin Mahyavanshi will partially reduce their holdings through the offer. The OFS also includes participation from prominent investors such as Kunal Shah, Nexus Venture Partners, Peak XV Partners, Blume Ventures and GGV Capital.
The allocation structure follows the standard regulatory framework for mainboard IPOs. Qualified Institutional Buyers (QIBs) have been allocated 75 per cent of the issue, while Non-Institutional Investors (NIIs) will receive 15 per cent. Retail investors have been allotted 10 per cent of the total issue size.
This structure is designed to ensure broad participation across institutional and retail investor categories.
Strong revenue growth despite continued losses
Turtlemint reported a significant improvement in its financial performance during FY25, driven by business expansion and growing insurance distribution volumes.
The company recorded revenue of Rs 662.7 crore in FY25, a substantial increase compared to Rs 78.6 crore reported in FY24. The sharp rise reflects strong growth in customer acquisition, policy distribution and platform activity.
However, despite the surge in revenue, profitability remains a challenge. The company’s net loss widened marginally to Rs 194.1 crore in FY25 from Rs 193.3 crore in the previous financial year.
Investors are likely to closely examine the company’s path to profitability while assessing its long-term growth prospects in the competitive insurtech market.
How the company plans to use IPO proceeds
The proceeds from the fresh issue will primarily be used to strengthen the company’s technology and operational capabilities.
Turtlemint plans to invest in cloud infrastructure and server capacity to support future growth. The company will also utilise funds to expand its technology and product teams, enhance marketing initiatives and meet lease-related obligations.
Additionally, part of the capital will be invested in its wholly-owned subsidiary TIB. The company also intends to support working capital requirements and explore inorganic growth opportunities through acquisitions and strategic investments.
Management believes these investments will help strengthen the platform’s market position and support long-term expansion.
Turtlemint’s business model and market presence
Founded in 2015 by Dhirendra Mahyavanshi and Anand Prabhudesai, Turtlemint has emerged as one of India’s prominent insurance distribution platforms.
The company operates a technology-driven marketplace that connects customers with insurance products through a large network of advisors. According to the company, it has built a network of more than five lakh insurance advisors across the country.
Turtlemint also claims to have sold nearly 1.6 crore insurance policies and serves more than 1.2 crore customers. Its platform offers a range of insurance products, including health, life and motor insurance.
As India’s insurance penetration continues to improve, the company aims to benefit from growing demand for digital insurance solutions and advisory services.
Key intermediaries managing the issue
The IPO is being managed by a consortium of leading investment banks. ICICI Securities, Jefferies India, JM Financial and Motilal Oswal Investment Advisors are acting as the book-running lead managers for the issue.
KFin Technologies has been appointed as the registrar to the IPO and will oversee allotment and investor-related processes.
With strong revenue growth, a sizeable distribution network and an expanding customer base, Turtlemint’s IPO is expected to attract attention from both institutional and retail investors. However, the subdued GMP and continued losses suggest that investors may carefully evaluate the company’s valuation and profitability outlook before making investment decisions.
Comments are closed.